FRESCO-2: Analyzing Fruquintinib for Refractory Metastatic Colorectal Cancer

Cathy Eng, MD, FACP, FASCO, Vanderbilt University Medical Center, provides an in-depth review of the FRESCO-2 trial that examined the efficacy of fruquintinib for refractory metastatic colorectal cancer.
Dr. Eng discusses how the trial results differ from the original FRESCO trial, and how fruquintinib differs from other VEGFR inhibitors.